Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Interventions: DRUG: Neratinib|DRUG: Fulvestrant|DRUG: Trastuzumab
Sponsor: Puma Biotechnology, Inc.